Xilio Therapeutics(US:XLO) Globenewswireยท2025-09-09 11:30Core Insights - Xilio Therapeutics has initiated patient dosing in Phase 2 of the clinical trial for efarindodekin alfa (XTX301), a tumor-activated IL-12, demonstrating promising anti-tumor activity in patients with advanced solid tumors [1][2] - The company achieved a $17.5 million development milestone under its license agreement with Gilead Sciences, extending its cash runway into the first quarter of 2027 [1][6] Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [11] - The company is leveraging its proprietary platform to advance a pipeline of novel tumor-activated immuno-oncology molecules [11] Clinical Trial Details - Efarindodekin alfa (XTX301) is designed to stimulate anti-tumor immunity and reprogram the tumor microenvironment of poorly immunogenic "cold" tumors to a more inflamed state [3][10] - The ongoing Phase 1/2 clinical trial is evaluating efarindodekin alfa as a monotherapy in patients with advanced solid tumors, with the Phase 2 portion expected to enroll approximately 40 patients [10] Financial Position - As of June 30, 2025, Xilio had cash and cash equivalents of $121.6 million, which, along with the recent milestone payment, is expected to fund operations into the first quarter of 2027 [5][6] Collaboration with Gilead - In March 2024, Xilio entered into an exclusive global license agreement with Gilead for the development and commercialization of efarindodekin alfa [7][10] - If Gilead exercises its option for efarindodekin alfa, Xilio could receive up to $500 million in specified milestones and tiered royalties on global net product sales [9]